Valdecantos et al. employed two NAFLD animal models (MCD diet and HFD mice), which underwent partial hepatectomy after treatment with G49, a dual GLP-1/GCG receptor agonist. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.